NUKAGA, S., NAOKI, K., KAMO, T., MASUZAWA, K., YASUDA, H., SOEJIMA, K., & BETSUYAKU, T. (2016). Alectinib as a treatment option following recovery from crizotinib-induced interstitial lung disease in patients with anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. Mol Clin Oncol.

NUKAGA, SHIGENARI, KATSUHIKO NAOKI, TETSURO KAMO, KEITA MASUZAWA, HIROYUKI YASUDA, KENZO SOEJIMA, and TOMOKO BETSUYAKU. "Alectinib As a Treatment Option Following Recovery From Crizotinib-induced Interstitial Lung Disease in Patients With Anaplastic Lymphoma Kinase-positive Advanced Non-small-cell Lung Cancer." Mol Clin Oncol 2016.

NUKAGA, SHIGENARI, et al. "Alectinib As a Treatment Option Following Recovery From Crizotinib-induced Interstitial Lung Disease in Patients With Anaplastic Lymphoma Kinase-positive Advanced Non-small-cell Lung Cancer." Mol Clin Oncol 2016.